Dow asks SCOTUS to review $445m award dispute
15-09-2017
Fed Circuit erred in Sandoz v Amgen, says solicitor general
28-02-2017
sprng23 / iStockphoto.com
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), has filed a brief in support of Sandoz’s petition for certiorari in the pending Sandoz v Amgen case.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biosimilar, biologics, patent, Biosimilars Council, Association for Accessible Medicines, SCOTUS, Sandoz, Amgen, BPCIA
